Dengue Clinical Trial
Official title:
Effectiveness of the Tetravalent Dengue Vaccine, CYD-TDV (Dengvaxia®) in the Philippines
Verified date | May 2023 |
Source | University of the Philippines |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is an observational study that aims to determine the effectiveness of a tetravalent dengue vaccine (CYD-TDV) when given through a community-based immunization program against hospitalized and /or severe virologically confirmed dengue.
Status | Completed |
Enrollment | 2081 |
Est. completion date | April 30, 2023 |
Est. primary completion date | November 30, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 9 Years to 14 Years |
Eligibility | Inclusion Criteria: CASE-CONTROL STUDIES - For a suspected case to be enrolled in the study, he/she should: - Provide signed informed consent and assent (as applicable) - Be within the age group eligible to receive the dengue vaccine at the time of mass vaccination (i.e. no condition that would have made him/her ineligible for dengue vaccination) - Be admitted in any of the participating hospitals for suspected dengue - Have =5 days history of fever. - For the case to be included in the analysis, the participant must meet all the inclusion criteria above plus have virologically-confirmed dengue infection by RT-PCR - For controls to be recruited into the study, he/she should: - Provide signed informed consent and assent (as applicable) - Be age and sex-matched to the case - Be from the same community as the matched case - Be eligible to have received dengue vaccine during the community-based dengue immunization campaign in 2017 (i.e. no condition that would have made him/her ineligible for dengue vaccination) - Have had no episode of clinically-diagnosed or laboratory-confirmed dengue fever from the start of the community -based dengue immunization campaign to the focal time (the date of onset of dengue fever in the matched case) - Should not have been previously recruited as a control. Exclusion Criteria: • Any subject whose parent/guardian refuse to provide informed consent and/or assent. - In addition, the following conditions automatically exclude children from the dengue mass immunization: - Children <9 years or adults older than 45 years of age - Anyone who is allergic or has had an allergic reaction to a prior dose or to any component of the dengue vaccine - Recipient of blood product in the last 3 months - Immunocompromised individuals, due to but not limited to genetic defects, HIV infection, or therapies that affect the immune system such as high-dose corticosteroids or chemotherapy - Recipient of any vaccine within the past month - History of bleeding disorder - Pregnant or breastfeeding women - Enrolled in dengue vaccine Phase 3 clinical study |
Country | Name | City | State |
---|---|---|---|
Philippines | Cebu Provincial Hospital - Balamban | Balamban | Cebu |
Philippines | Cebu Provincial Hospital - Bogo | Bogo City | Cebu |
Philippines | Cebu Provincial Hospital - Danao | Danao | Cebu |
Philippines | Eversley Childs Sanitarium and General Hospital | Mandaue City | Cebu |
Lead Sponsor | Collaborator |
---|---|
University of the Philippines | Research Institute for Tropical Medicine, Philippines, Sanofi Pasteur, a Sanofi Company |
Philippines,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | hospitalized and / or severe virologically confirmed dengue | The primary outcome are children who are hospitalized and/or severe virologically confirmed dengue | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321264 -
Educational Intervention to Promote Control Behaviors and Prevention of Dengue
|
N/A | |
Completed |
NCT01436396 -
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
|
Phase 3 | |
Completed |
NCT01391819 -
Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children
|
N/A | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02833584 -
Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults
|
N/A | |
Completed |
NCT02433652 -
Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
|
Phase 1 | |
Enrolling by invitation |
NCT02016027 -
Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter
|
Phase 1 | |
Completed |
NCT01477671 -
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
|
N/A | |
Recruiting |
NCT00377754 -
Prospective Study of Infant Dengue
|
N/A | |
Recruiting |
NCT05919277 -
A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
|
||
Recruiting |
NCT04582474 -
Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso
|
N/A | |
Completed |
NCT01983553 -
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
|
||
Active, not recruiting |
NCT05967455 -
Homologous Re-infection With Dengue 1 or Dengue 3
|
Phase 1 | |
Completed |
NCT03631719 -
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
|
||
Recruiting |
NCT02606019 -
The Use of Biomarkers in Predicting Dengue Outcome
|
N/A | |
Completed |
NCT02372175 -
Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain
|
Phase 1 | |
Active, not recruiting |
NCT01696422 -
Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine
|
Phase 2 | |
Completed |
NCT00993447 -
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
|
Phase 2 | |
Completed |
NCT00375726 -
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults
|
Phase 1 | |
Completed |
NCT05153018 -
Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu
|
N/A |